Tivozanib Completed Phase 1 Trials for Hepatic Impairment Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT01631097A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function